Drug Trial Radar · NCT03767855
A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
114
Actual
Start
Dec 4, 2018
Primary completion
Jan 3, 2020
Study completion Jan 3, 2020
Sponsor
- Lead sponsor
- CytokineticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in healthy subjects. 2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses. 3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses. 4. Determine the effect of doses of CK-3773274 on the pumping function of the heart. 5. Evaluate the effect of cytochrome genetic variants on how the body metabolizes CK-3773274. 6. Evaluate the effect of a meal on how much CK-3773274 is in the blood in healthy adult subjects. 7. Evaluate whether the amount of CK-3773274 in the blood is the similar for both the tablet and granules in capsule forms of the drug.
Conditions
- Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Healthy Subjects
Interventions
CK-3773274 - Granules in CapsuleDrug
CK-3773274 formulated as granules in capsule
Placebo - Granules in CapsuleDrug
Placebo formulated as granules in capsule
CK-3773274 - TabletsDrug
CK-3773274 formulated as tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse events and Safety Signals observed during single and multiple ascending doses of CK-3773274 administered orally to healthy adult subjects.Time frame: SAD Cohorts: Day -1 - Day 10; CYP2D6 Cohort: Day -1 - Day - 24; MAD Cohorts: Day -1 - Day 27; Food Effect Cohort: Day -1 - Day 24; relative Bioavailability Cohort: Day -1 - Day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Site
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.